Sigma Planning Corp Invests $217,000 in DexCom, Inc. (NASDAQ:DXCM)

Sigma Planning Corp acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 1,456 shares of the medical device company’s stock, valued at approximately $217,000.

Other institutional investors have also recently modified their holdings of the company. Gradient Investments LLC acquired a new stake in shares of DexCom in the second quarter worth $25,000. Virtus ETF Advisers LLC acquired a new stake in shares of DexCom in the second quarter worth $29,000. CSat Investment Advisory L.P. acquired a new stake in shares of DexCom in the second quarter worth $31,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of DexCom in the second quarter worth $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of DexCom in the second quarter worth $37,000. Institutional investors and hedge funds own 96.55% of the company’s stock.

A number of analysts have recently weighed in on the stock. Oppenheimer boosted their price objective on shares of DexCom from $180.00 to $205.00 in a research note on Thursday, November 7th. Robert W. Baird boosted their price objective on shares of DexCom from $195.00 to $240.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Raymond James boosted their price objective on shares of DexCom from $172.00 to $189.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Jefferies Financial Group boosted their price objective on shares of DexCom from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, UBS Group boosted their target price on shares of DexCom from $160.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $190.67.

DXCM stock traded down $1.15 on Tuesday, reaching $204.53. 22,903 shares of the company were exchanged, compared to its average volume of 1,148,939. DexCom, Inc. has a 12 month low of $105.05 and a 12 month high of $205.93. The stock’s fifty day moving average price is $157.33 and its 200 day moving average price is $147.12. The firm has a market capitalization of $18.13 billion, a PE ratio of 683.90 and a beta of 0.64. The company has a debt-to-equity ratio of 1.41, a current ratio of 5.63 and a quick ratio of 5.26.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.45. The firm had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The business’s revenue for the quarter was up 48.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. As a group, research analysts expect that DexCom, Inc. will post 1.41 EPS for the current fiscal year.

In other DexCom news, insider Andrew K. Balo sold 9,107 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $151.56, for a total value of $1,380,256.92. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $156.12, for a total transaction of $1,561,200.00. The disclosure for this sale can be found here. Insiders sold a total of 105,222 shares of company stock worth $16,407,406 in the last three months. Insiders own 0.88% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: What are the benefits of investing in REITs?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.